Boundless Bio, Inc.
No enriched coverage for $BOLD in the last 7 days.
Boundless Bio (BOLD) and Backblaze (BLZE) stocks surged 85% and 43% respectively, while Quantinuum (QNT) gained 13%. BOLD rose after a merger deal with Serapha Bio, including $230M in funding. BLZE reached a 2-year high after a $335M AI cloud deal. QNT hit a record high following a White House quantum tech development order.
Boundless Bio, Inc. (BOLD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously announced, on June 22, 2026, Boundless Bio, Inc., a Delaware corporation (“Boundless Bio”), Boulder Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of Boundless Bio (“Merger Sub”), and Seraph
Several biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.
Recent BOLD coverage spans insider activity, market movers and financial news.
In the last 30 days, BOLD insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($54K). The most active reporter was TANG KEVIN with 1 filing.
Positive merger and capital raise likely boost valuation.
Amendment may affect share dilution, warrant issuance and post‑merger ownership structure.
First‑in‑human data could be a catalyst for valuation.
A 10% owner open-market purchase is a modest bullish signal, but it is not a fundamental catalyst like earnings, guidance, or a deal.
This is an insider open-market purchase disclosed via Form 4, which can modestly support sentiment but is not a fundamental catalyst by itself.
AlphAI scores every news story that mentions BOLD with an AI model for sentiment and relevance, and aggregates insider trades from Boundless Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Boundless Bio (BOLD) and Backblaze (BLZE) stocks surged 85% and 43% respectively, while Quantinuum (QNT) gained 13%. BOLD rose after a merger deal with Serapha Bio, including $230M in funding. BLZE reached a 2-year high after a $335M AI cloud deal. QNT hit a record high following a White House quantum tech development order.
2 min readBoundless Bio, Inc. (BOLD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously announced, on June 22, 2026, Boundless Bio, Inc., a Delaware corporation (“Boundless Bio”), Boulder Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of Boundless Bio (“Merger Sub”), and Seraph
2 min readSeveral biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.
3 min readTANG KEVIN purchased 63,969 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.43 ($2.43–$2.44, $0.16M total) across 3 trades over 2026-07-14 to 2026-07-16.
2 min readTANG KEVIN purchased 91,585 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.42 ($2.42–$2.48, $0.22M total) across 3 trades over 2026-07-09 to 2026-07-13.
1 min readA roundup of July 8, 2026 insider trades reported major buys in Mission Produce (AVO), where Globalharvest Holdings Venture Ltd bought 650,415 shares for about $8.28M at $12.73 avg, and Boundless Bio (BOLD), where Tang Capital bought 57,210 shares for about $141.9K. Major sells included Rocket Lab (RKLB) CEO Peter Beck selling about $286.4M and Dell (DELL) director Egon Durban/Silver Lake selling about $29.9M.
7 min readTANG KEVIN purchased 57,210 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.48 ($2.46–$2.49, $0.14M total) across 3 trades over 2026-07-06 to 2026-07-08.
2 min readInvesting.com reports US insider trades disclosed Thursday. Buys: JCTC ($25,871; 11,009 shares at $2.35), BGDE ($16.7M Series D at $1,000), HDSN (~764,202 shares for ~$4.48M), BOLD (~$268,880), and COLB ($22,477). Sells: CRWV CEO sold ~$37.7M; EWTX CSO sold ~$7.88M; ALAB director sold ~$5.62M.
6 min readTANG KEVIN purchased 107,463 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.50 ($2.49–$2.54, $0.27M total) across 4 trades over 2026-06-30 to 2026-07-02.
2 min readTANG KEVIN purchased 286,333 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.50 ($2.47–$2.56, $0.71M total) across 6 trades over 2026-06-25 to 2026-06-29.
2 min read